IMOJEV Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
IMOJEV General Information
Description
Japanese encephalitis vaccine intended for adults and children.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
- Paris
- France
Corporate Office
- Paris
- France
IMOJEV Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
IMOJEV Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
IMOJEV FAQs
-
Where is IMOJEV headquartered?
IMOJEV is headquartered in Paris, France.
-
What industry is IMOJEV in?
IMOJEV’s primary industry is Buildings and Property.
-
Is IMOJEV a private or public company?
IMOJEV is a Private company.
-
What is IMOJEV’s current revenue?
The current revenue for IMOJEV is .
-
Who are IMOJEV’s investors?
Sanofi has invested in IMOJEV.
-
When was IMOJEV acquired?
IMOJEV was acquired on 30-Nov-2022.
-
Who acquired IMOJEV?
IMOJEV was acquired by Substipharm.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process